Home Visit
Upload
.png)
BCR ABL1 Mutation Analysis Test
51+ booked in last 3 days
No special precautions
Sample Type
Blood
Recommended for
Male, Female
Report
Within 24 Hours
Blood test at Home
NABL & CAP Accredited Labs
Accurate & Quality Test Reports
Trusted by Leading Doctors & Hospitals
BCR ABL Test Overview
BCR-ABL1 Mutation Analysis is a diagnostic test used to detect mutations in the BCR-ABL1 fusion gene in Chronic Myeloid Leukemia (CML) patients. It serves as a crucial therapy resistance marker, as specific mutations in the BCR-ABL1 kinase domain can lead to resistance to tyrosine kinase inhibitors (TKIs), the mainstay of CML treatment. By identifying these mutations, the test helps guide treatment decisions by allowing for alternative therapy selection or dose adjustments to overcome drug resistance. Regular monitoring of BCR-ABL1 mutations during treatment enables early detection of resistance and timely intervention, optimizing treatment outcomes in CML patients.
BCR ABL1 Mutation Analysis Test Price
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the BCR ABL1 Mutation Analysis Test with a clear pricing structure.
The BCR ABL1 Mutation Analysis Test Price in Mumbai is ₹ 10,710 .
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
BCR ABL1 Mutation Analysis detects genetic mutations in the BCR ABL1 fusion gene, specifically for CML.
• To identify genetic mutations in the BCR ABL1 gene for patients with CML • To guide treatment decisions by determining therapy resistance markers • To monitor treatment effectiveness and assess the need for changes in therapy • To provide valuable information for personalized treatment plans
BCR ABL1 Mutation Analysis is recommended for • patients diagnosed with CML, • patients with suspected therapy resistance or treatment failure, • patients whose treatment response needs to be monitored, and • patients requiring personalised treatment plans based on genetic information.
The presence of BCR ABL1 gene mutations may indicate therapy resistance in CML. Abnormal results help doctors identify appropriate treatment options.
During this test, a sample of 5–10 ml of EDTA whole blood will be collected. The sample is sent for analysis using Sanger Sequencing.
• Clinical diagnosis, test prescription, and TRF are mandatory. • Follow any instructions provided by your doctor regarding medication or dietary restrictions. • Inform your doctor if you have any specific requirements.
• Complete Blood Count (CBC): To assess the overall blood cell counts and morphology • BCR ABL1 Quantitative PCR: To monitor treatment response and measure disease burden • Bone Marrow Aspiration and Biopsy: To evaluate the extent of bone marrow involvement
Genetic Testing for Therapy Resistance in Chronic Myeloid Leukaemia
Chronic myeloid leukaemia is a type of cancer that affects the white blood cells. It is characterised by the overproduction of abnormal white blood cells in the bone marrow. CML is often associated with a genetic abnormality known as the Philadelphia chromosome.
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.
1707898101.webp)
WhatsApp